ArticleTranslational andrology and urology2026
Identification of pyroptosis-related molecular subtypes and development of a subtype-derived six-gene prognostic signature for bladder cancer.
Article in Translational andrology and urology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Pyroptosis is an inflammatory form of programmed cell death that may remodel the tumor immune microenvironment and influence clinical outcomes. However, the prognostic value of pyroptosis-related molecular patterns and their translational implications in bladder cancer remain incompletely defined. This study aimed to identify pyroptosis-related molecular subtypes, develop and externally validate a subtype-derived prognostic signature, and explore its associations with immune and therapeutic features in bladder cancer. Methods: The Cancer Genome Atlas-bladder cancer cohort (TCGA-BLCA) was used as the development cohort, GSE13507 and GSE31684 as external validation cohorts, and IMvigor210 as an exploratory immunotherapy-treated cohort. Pyroptosis-related molecular subtypes were identified by non-negative matrix factorization (NMF), and pathway activity and immune infiltration were assessed by gene set variation analysis (GSVA) and single-sample gene set enrichment analysis (ssGSEA). A subtype-derived six-gene prognostic signature was developed using least absolute shrinkage and selection operator Cox (LASSO-Cox) regression, and performance was evaluated by Kaplan-Meier analysis, time-dependent receiver operating characteristic (ROC) curves, and calibration. Results: Two pyroptosis-related molecular subtypes (C1/C2) with distinct survival and immune characteristics were identified. A subtype-derived six-gene prognostic signature comprising Conclusions: We established pyroptosis-related molecular subtypes and developed a subtype-derived six-gene prognostic signature that was evaluated across multiple independent cohorts. The model is associated with immune microenvironment features and genomic context, and offers translational clues for immunotherapy and targeted strategies, warranting further prospective and experimental validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.